Degradomics-Based Analysis of Tetanus Toxoids as a Quality Control Assay

Currently, batch release of toxoid vaccines, such as diphtheria and tetanus toxoid, requires animal tests to confirm safety and immunogenicity. Efforts are being made to replace these tests with in vitro assays in a consistency approach. Limitations of current in vitro assays include the need for reference antigens and most are only applicable to drug substance, not to the aluminum adjuvant-containing and often multivalent drug product. To overcome these issues, a new assay was developed based on mimicking the proteolytic degradation processes in antigen-presenting cells with recombinant cathepsin S, followed by absolute quantification of the formed peptides by liquid chromatography-mass spectrometry. Temperature-exposed tetanus toxoids from several manufacturers were used as aberrant samples and could easily be distinguished from the untreated controls by using the newly developed degradomics assay. Consistency of various batches of a single manufacturer could also be determined. Moreover, the assay was shown to be applicable to Al(OH)3 and AlPO4-adsorbed tetanus toxoids. Overall, the assay shows potential for use in both stability studies and as an alternative for in vivo potency studies by showing batch-to-batch consistency of bulk toxoids as well as for aluminum-containing vaccines.

[1]  W. Jiskoot,et al.  Formaldehyde treatment of proteins enhances proteolytic degradation by the endo-lysosomal protease cathepsin S , 2020, Scientific Reports.

[2]  K. Edler,et al.  Ensilicated tetanus antigen retains immunogenicity: in vivo study and time-resolved SAXS characterization , 2020, Scientific Reports.

[3]  Rob J Vandebriel,et al.  Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop. , 2017, Biologicals : journal of the International Association of Biological Standardization.

[4]  Julian E. Fuchs,et al.  Fold stability during endolysosomal acidification is a key factor for allergenicity and immunogenicity of the major birch pollen allergen , 2016, The Journal of allergy and clinical immunology.

[5]  H. Brandstetter,et al.  Protease recognition sites in Bet v 1a are cryptic, explaining its slow processing relevant to its allergenicity , 2015, Scientific Reports.

[6]  R. Cole,et al.  Divergent Paths for the Selection of Immunodominant Epitopes from Distinct Antigenic Sources , 2014, Nature Communications.

[7]  G. Zlabinger,et al.  A hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and T‐cell activation , 2012, Allergy.

[8]  P. Briza,et al.  Assessing Protein Immunogenicity with a Dendritic Cell Line-Derived Endolysosomal Degradome , 2011, PloS one.

[9]  Viktorya Aviyente,et al.  Deamidation of asparagine residues: direct hydrolysis versus succinimide-mediated deamidation mechanisms. , 2009, The journal of physical chemistry. A.

[10]  I. Mellman,et al.  Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis , 2006, The Journal of experimental medicine.

[11]  W. Hennink,et al.  Identification of Formaldehyde-induced Modifications in Proteins , 2004, Journal of Biological Chemistry.

[12]  W. Hennink,et al.  Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines. , 2003, Vaccine.

[13]  H. Meiring,et al.  Nanoscale LC–MS(n): technical design and applications to peptide and protein analysis , 2002 .

[14]  N. K. Steede,et al.  Proteolytic Sensitivity and Helper T-cell Epitope Immunodominance Associated with the Mobile Loop in Hsp10s* , 2002, The Journal of Biological Chemistry.

[15]  Martha H. Roper,et al.  Tetanus toxoid , 2018, Reactions Weekly.

[16]  J M Chapsal,et al.  The vaccines consistency approach project: an EPAA initiative. , 2015, Pharmeuropa bio & scientific notes.

[17]  Marlies Halder,et al.  The consistency approach for quality control of vaccines - a strategy to improve quality control and implement 3Rs. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[18]  H. Kirschke,et al.  [34] Cathepsin S and related lysosomal endopeptidases , 1994 .

[19]  A. Tasman,et al.  Consistency in potency assay of tetanus toxoid in mice. , 1959, Bulletin of the World Health Organization.